Joey Chau

Joey has advised on a number of significant M&A transactions, including the following:

2024

• CITIC Capital on its HK$1.46 billion sale of a 20.32% stake in AsiaInfo Technologies Limited (HKSE: 1675) to AsiaInfo Security Technologies Co., Limited (688225.SH)
• Oaktree Capital on its cornerstone investment in the listing of China Resources Beverage (HKSE: 2460) on the Hong Kong Stock Exchange
• Edding Group on its reverse takeover with Genor Biopharma (HKSE: 6998)
• PCCW (HKSE: 0008) on its HK$280 million PIPE investment in the de-SPAC merger of HK Acquisition Corporation (HKSE: 7841) and Synagistics Pte. Ltd.
• Morgan Stanley, as the financial adviser to An Ke Technology and China Ping An Insurance, on the mandatory unconditional cash offers for Lufax Holding (HKSE: 6623; NYSE: LU)
• CICC, as financial adviser, on:
  
  • Shanghai Fosun New Medicine’s privatization of Shanghai Henlius Biotech (HKSE: 2696)
  • Liaoning Financial’s privatization of Bank of Jinzhou (HKSE: 416)
• J.P. Morgan, as financial adviser to L’Occitane Groupe S.A., on its privatization of L’Occitane International S.A. (HKSE: 973)
• GL Capital (as the offeror) on its privatization of SciClone Pharmaceuticals (HKSE: 6600)
• Independent Board Committee of Vinda International Holdings (HKSE: 3331) on the voluntary conditional cash offer from Isola Castle Ltd
• CIMC Vehicles (HKSE: 1839) (as the offeror) on its privatization

2023

• ZG Group on its business combination with Aquila Acquisition Corporation
• MoneyHero Group on its business combination with Bridgetown (NASDAQ: BTWN)
• CICC, as financial adviser to Inner Mongolia Yitai Coal (HKSE: 3948; SHSE: 900948), on its privatization
• NetDragon (HKSE: 777) on the spin-off of its core overseas education business through its subsidiary, and the merger of its subsidiary with Gravitas Education Holdings, Inc. (NYSE: GEHI)
• Wynn Macau (HKSE: 1128) on its issuance of US$600 million of convertible bonds
• Power Heritage Group (as the offeror) on its privatization of Jiangnan Group (HKSE: 1366)
• Bain Capital on its minority investment in EcoCeres, a subsidiary of The Hong Kong and China Gas Company Limited (Towngas) (HKSE: 0003)
• SciClone Pharmaceuticals (HKSE: 6600) on its HK$780 million share buyback by way of general offer

2022

• Link REIT (HKSE: 823) on its S$2.16 billion acquisition of a portfolio of assets in Singapore
• Skyworth Group (HKSE: 00751) on its HK$380 million share buyback by way of general offer
• Oaktree Capital on its cornerstone investment in China Tourism Group Duty Free Corporation’s listing on the Hong Kong Stock Exchange
• CICC, as financial adviser, on:
  
  • Shenzhen EVOC Intelligence Technology’s privatization of EVOC Intelligent Technology (HKSE: 2308)
  • Luxshare Precision’s takeover of Time Interconnect Technology (HKSE: 1729)
  • Beijing Chunhui’s privatization of Guodian Technology & Environment Group (HKSE: 1296)
• Oaktree Capital on its cornerstone investment in Thai Life Insurance’s THB37.1 billion (approximately $1 billion) listing on the Stock Exchange of Thailand
• COFCO Beverages, a subsidiary of COFCO Corporation and China Foods Limited (HKSE: 506), in the acquisition of all of the equity interests in certain wholly-owned subsidiaries of Coca Cola Bottlers Manufacturing Holdings, a joint venture ultimately owned by The Coca-Cola Company, Swire Pacific Limited (HKSE: 00019 and HKSE: 00087) and COFCO Beverages
• Hypebeast (HKSE: 00150) on its proposed listing on NASDAQ through a business combination with Iron Spark (NASDAQ: ISAA)
• Sequoia China Infrastructure Fund on its investment in GDS Holdings (NASDAQ: GDS; HKSE: 9698)

2021

• A consortium of investors, comprising Centurium Capital, PW Medtech Group Limited (HKSE: 1358), CITIC Capital, Hillhouse Capital, Temasek and Marc Chan, on the US$4.6 billion take-private of China Biologic Products (NASDAQ: CBPO)
• CICC, as financial adviser, on:
  
  • Yunan Baiyao’s takeover of Ban Loong Holdings (HKSE: 30)
  • The take-private of Suchuang Gas (HKSE: 1430) by China Resources Gas
  • China Modern Dairy (HKSE: 1117)’s acquisition of Inner Mongolia Fuyuan International
• UBS AG, as financial adviser to CPF Investment Limited, on its privatization of C.P. Pokphand (HKSE: 43)
• Artisan Acquisition Corp. (NASDAQ: ARTAU) on its business combination with Prenetics Group
• Carlyle on its US$210 million investment in HUTCHMED
• JD Property (as the offeror) on its US$2 billion take-private of China Logistics Property Holdings (HKSE: 1589)
• Oaktree Capital on its US$100 million cornerstone investment in JD Logistics’ listing on the Hong Kong Stock Exchange
• CMGE Technology Group (HKSE: 302) on its US$100 million issue of new shares to Bilibili Inc. (NASDAQ: BILI)
• J.P. Morgan, as financial adviser to Country Garden Services (HKSE: 6098), on its privatization of Sichuan Languang Justbon Services Group (HKSE: 2606)
• Ocean Link Partners and Sequoia Capital China (as the consortium offeror) on the take-private of Zhejiang New Century Hotel Management

2020

• CICC, as financial adviser, on:
  
  • Luxvisions Innovation Technology Limited’s takeover of Cowell (HKSE: 1415)
  • Shandong Gold Mining (HKSE: 1787)’s take-private of Hengxing Gold Holding (HKSE: 2303)
  • SanXing Trade’s privatization of Changshouhua Food Company (HKSE: 1006)
• Car Inc. (HKSE: 699) on its take-private by MBK Partners and its issue of US$175 million of convertible bonds to MBK Partners Special Situations fund
• Loyal Valley Capital, as a member of an investor consortium, on the privatization of O-Net Technologies (HKSE:877)
• Advantage Partners on its primary and secondary general partner share sale to, and strategic partnership with, Tokyo Century Corporation
• Li & Fung on US$100 million strategic investment by JD.com
• Huatai Financial Holdings, as financial adviser, on the privatization of Huarong Investment Stock Corporation Limited (HKSE: 2277)
• Skyworth Group (HKSE: 00751) on its HK$1.1 billion share buyback by way of general offer
• Lilly Asia Ventures on its cornerstone investment in Peijia Medical Limited
• GLP and the consortium offeror comprising the Fung family and GLP, on its privatization of Li & Fung (HKSE: 494)

2019

• TPV Technology (HKSE: 903, SGX: T18) on its privatization by China Electronics Corporation
• Nan Fung Group on its US$110 million acquisition of a minority stake in Hong Kong International Construction Investment Management Group (HKSE: 687)
• Blackstone on its US$400 million subscription of H shares convertible bonds in Hong Kong-listed YiChang HEC ChangJiang Pharmaceutical (HKSE: 1558)

2018

• Loyal Valley Capital and TR Capital on their cornerstone investments in the US$414 million listing of Shanghai Junshi Biosciences on the Hong Kong Stock Exchange

• UBS AG, as financial adviser, on the US$671 million unsolicited conditional voluntary general offer of Spring REIT by PAG Real Estate

• Malaysian sovereign fund on its investment in the US$14 billion Series C equity financing of Ant Financial

2017

• Bank of America Merrill Lynch, as financial adviser, on the $6.8 billion privatization of Belle International

• MicroPort Scientific Corporation (HKSE: 853) on its US$190 million acquisition of the Cardiac Rhythm Management business of LivaNova PLC

• Midea (as the offeror) on its privatization of Welling

• Ally Bridge Group (as a joint offeror) on its US$300 million privatization of Shandong Luoxin Pharmaceutical Group (HKSE: 8058)

• The Carlyle Group, CITIC Limited and CITIC Capital Holdings on the US$2.08 billion acquisition of the McDonald’s operations in China and Hong Kong

2016

• COFCO Coca-Cola Beverages, a subsidiary of China Foods Limited (HKSE: 506) and a subsidiary of state-owned COFCO Corporation, on its acquisition of the bottling operations from The Coca-Cola Company and Swire Beverages

• J.P. Morgan, as financial adviser, on CVC Capital Partners-led funds’ US$1.1 billion privatization of Nirvana Asia (HKSE: 1438)

• Ascendent Capital Partners on the takeover of China Automation Group (HKSE: 569)

• Malaysian sovereign fund on its investment in Cainiao and WeLab

2015

• China Grand Automotive Services (SSE: 600297) (as the offeror) on its US$1.5 billion partial offer for Baoxin Auto Group (HKSE: 1293)

• Vipshop (NYSE: VIPS) on its €30 million investment in the IPO of Showroomprive.com (IPO-SHOW.PA) on Euronext Paris

• China Traditional Chinese Medicine (HKSE: 570) on its HK$8.2 billion equity placing and its US$1.43 billion acquisition of Jiangyin Tianjiang Pharmaceutical

• Pokka Corporation (Singapore) on its sale of Pokka Corporation (HK) and Pokka Coffee (Macau) to Xiao Nan Guo Restaurants (HKSE: 3666)

2014

• Shanghai Pudong Science and Technology Investment on its US$693 million acquisition of NASDAQ-listed Montage Technology Group

• CCB International on its purchase of secured notes and warrants issued by China Gui Tea

• 21st Century Fox on its sale of a 49.9% stake in Star China TV to China Media Capital

2012–2013

• Beijing Wangfujing (as the offeror) on its take-private of PCD Stores

• NCGA Holdings on its US$305 million acquisition by Baoxin Auto Group (HKSE: 1293)

• CITIC Securities (HKSE: 6030) on its US$1.252 billion purchase of CLSA

2011–2012

• TPV Technology (HKSE: 903) on its acquisition of a 70% interest in a joint venture company which owns and controls the entire television business of Philips

Skadden, Arps, Slate, Meagher & Flom (Hong Kong)